Trial · NCT00518713
Results by group152
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 152
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). | Clobazam Low Dose | 41.2 | Full Range -119 to 100 | Percent Reduction | |
| Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). | Clobazam Medium Dose | 49.4 | Full Range -262 to 100 | Percent Reduction | |
| Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). | Clobazam High Dose | 68.3 | Full Range -39 to 100 | Percent Reduction | |
| Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). | Placebo | 12.1 | Full Range -374 to 100 | Percent Reduction | |
| Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | Clobazam Low Dose | 47.8 | Full Range -103 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | Clobazam Medium Dose | 58.9 | Full Range -147 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | Clobazam High Dose | 71.0 | Full Range -58 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | Placebo | 18.6 | Full Range -106 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | Clobazam Low Dose | 44.1 | Full Range -36 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | Clobazam Medium Dose | 38.8 | Full Range -433 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | Clobazam High Dose | 64.9 | Full Range -125 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | Placebo | 21.1 | Full Range -284 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | Clobazam Low Dose | 31.8 | Full Range -477 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | Clobazam Medium Dose | 56.0 | Full Range -228 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | Clobazam High Dose | 68.0 | Full Range -117 to 100 | Percent reduction | |
| Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | Placebo | -0.1 | Full Range -948 to 100 | Percent reduction | |
| Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period). | Clobazam Low Dose | ≥ 25% reduction | 34 | 0.83 to 4.20 | Percent of responders |
| Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period). | Clobazam Medium Dose | ≥ 25% reduction | 46 | 1.61 to 9.59 | Percent of responders |
| Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period). | Clobazam High Dose | ≥ 25% reduction | 41 | 2.14 to 14.30 | Percent of responders |
| Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period). | Placebo | ≥ 25% reduction | 28 | Percent of responders |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00518713/results